Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28207642 | 0.85 | FFAR3 (0.39) | FFAR3 | |
| SCHEMBL27766856 | 0.80 | — | — | |
| SCHEMBL28089439 | 0.79 | — | — | |
| SCHEMBL27708887 | 0.75 | — | — | |
| SCHEMBL30075879 | 0.74 | FFAR3 (0.33) | FFAR3 | |
| SCHEMBL2118073 | 0.74 | FFAR3 (0.33) | FFAR3 | |
| Lithium SCHEMBL30871974 | 0.73 | FFAR3 (0.32) | FFAR3 | |
| Potassium SCHEMBL30871995 | 0.73 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL30871990 | 0.73 | FFAR3 (0.32) | FFAR3 | |
| SCHEMBL29249163 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2316819-B1 | Self-assembled nanostructures | XEROX CORP (US) | 2017-11-08 | — | — | EP | disclosed |
| US-8703988-B2 | Self-assembled nanostructures | XEROX CORPORATION (US) | 2014-04-22 | — | — | US | disclosed |
| US-20110311813-A1 | SELF-ASSEMBLED NANOSTRUCTURES | NATIONAL RESEARCH COUNCIL OF CANADA (CA) | 2011-12-22 | — | — | US | disclosed |
| EP-2316819-A2 | Self-assembled nanostructures | Xerox Corporation (US) | 2011-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110311813-A1 | SELF-ASSEMBLED NANOSTRUCTURES | ARG1, H1-3, H1-4 | FFAR3 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.